INAB net incomeQ3 2026-$4.59M
INAB net income was -$4.59M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$3.85M a year earlier. For the full fiscal 2025 it was -$19.44M, compared with -$30.44M in fiscal 2024.
IN8bio Inc. (INAB) financials
For the twelve months ended Sep 30, 2026, IN8bio Inc. reported -$19.41M of net income.
- Net income, TTM
- -$19.41M
- Cash
- $14.15M
- Market cap
- $9.2M
FY2020FY2025
INAB revenue and earnings growth
INAB EPSQ3 2026-$0.24
INAB diluted EPS was -$0.24 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$4.44.
INAB free cash flowQ3 2025-$3.52M
INAB free cash flow was -$3.52M in fiscal Q3 2025 (ended Sep 30, 2025), compared with -$6.11M a year earlier.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Research and development | $10.21M | $16.96M | $16.83M | $14.06M | $7.35M | $5.38M |
| Selling, general and admin | $9.65M | $12.64M | $13.51M | $14.46M | $7.31M | $3.18M |
| Operating income | -$19.44M | -$30.44M | -$30.01M | -$28.52M | -$14.65M | -$8.56M |
| Pre-tax income | -$19.44M | -$30.68M | - | - | - | - |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$19.44M | -$30.44M | -$30.01M | -$28.52M | -$14.65M | -$8.56M |
| EPS, basic | -$4.44 | -$17.05 | -$30.00 | -$40.80 | -$44.10 | -$90.60 |
| EPS, diluted | -$4.44 | -$17.05 | -$30.00 | -$40.80 | -$44.10 | -$90.60 |
| Diluted shares | 4.4M | 1.8M | 995,497.733 | 698,931.833 | 332,324.433 | 113,969.167 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $27.31M | $11.39M | $21.54M | $18.43M | $37.27M | $18.14M |
| Current assets | $27.88M | $12.58M | $24.63M | $22.23M | $38.98M | $18.14M |
| Total assets | $32.28M | $20.94M | $33.71M | $33.04M | $42.22M | $20.91M |
| Current liabilities | $3.16M | $3.08M | $5.39M | $5.82M | $2.26M | $2.57M |
| Total liabilities | $4.72M | $6.47M | $8.77M | $10.31M | $4.04M | $2.59M |
| Shareholders' equity | $27.56M | $14.48M | $24.94M | $22.73M | -$38.18M | -$16.58M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$12.71M | -$24.15M | -$23.34M | -$24.12M | -$13.51M | -$7.13M |
| Investing cash flow | $0 | -$187.0K | -$600.0K | -$3.71M | -$309.0K | $0 |
| Financing cash flow | $28.64M | $14.18M | $27.04M | $8.99M | $32.95M | $24.52M |
| Stock-based compensation | $3.19M | $5.00M | $4.37M | $3.47M | $2.19M | $357.0K |
Key ratios
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $2.60M | $2.49M | $2.61M | $2.65M | $2.10M | $2.49M | $2.97M | $3.59M | $3.31M | $5.16M | $4.90M | $4.52M |
| Selling, general and admin | $2.12M | $2.44M | $2.65M | $2.38M | $1.86M | $2.71M | $2.69M | $2.63M | $2.73M | $3.53M | $3.74M | $3.08M |
| Operating income | -$4.59M | -$4.78M | -$5.09M | -$4.94M | -$3.85M | -$5.09M | -$5.55M | -$6.16M | -$7.09M | -$8.63M | -$8.56M | -$7.60M |
| Net income | -$4.59M | -$4.78M | -$5.09M | -$4.94M | -$3.85M | -$5.09M | -$5.55M | -$6.16M | -$7.09M | -$8.63M | -$8.56M | -$7.60M |
| EPS, basic | -$0.24 | -$0.25 | -$0.26 | - | -$0.85 | -$1.24 | -$2.16 | - | -$4.49 | -$5.51 | -$6.00 | - |
| EPS, diluted | -$0.24 | -$0.25 | -$0.26 | - | -$0.85 | -$1.24 | -$2.16 | - | -$4.49 | -$5.51 | -$6.00 | - |
| Diluted shares | 19.5M | 19.5M | 19.5M | - | 4.5M | 4.1M | 2.6M | - | 1.6M | 1.6M | 1.4M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $14.15M | $18.13M | $22.16M | $27.31M | $10.96M | $13.50M | $12.16M | $11.39M | $4.26M | $10.48M | $13.27M | $21.54M |
| Current assets | $15.19M | $18.50M | $22.66M | $27.88M | $11.77M | $13.74M | $12.72M | $12.58M | $6.70M | $12.68M | - | $24.63M |
| Total assets | $18.70M | $21.75M | $26.27M | $32.28M | $16.77M | $19.37M | $19.87M | $20.94M | $15.97M | $22.50M | - | $33.71M |
| Current liabilities | $2.63M | $2.25M | $2.16M | $3.16M | $1.70M | $1.95M | $2.96M | $3.08M | $3.63M | $4.76M | - | $5.39M |
| Total liabilities | $4.52M | $3.38M | $3.48M | $4.72M | $3.58M | $4.13M | $5.99M | $6.47M | $7.38M | $8.88M | - | $8.77M |
| Shareholders' equity | $14.17M | $18.36M | $22.78M | $27.56M | $13.19M | $15.24M | $13.88M | $14.48M | $8.59M | $13.62M | $17.53M | $24.94M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.93M | -$3.75M | -$4.95M | -$2.14M | -$3.52M | -$3.93M | -$3.12M | -$4.03M | -$6.11M | -$6.09M | -$7.92M | -$4.85M |
| Capital expenditures | - | - | - | - | $0 | $0 | $0 | - | $0 | $21.0K | $50.0K | - |
| Free cash flow | - | - | - | - | -$3.52M | -$3.93M | -$3.12M | - | -$6.11M | -$6.11M | -$7.97M | - |
| Investing cash flow | $1.0K | -$233.0K | -$9.0K | $0 | $0 | $0 | $0 | -$33.0K | $0 | -$83.0K | -$71.0K | -$72.0K |
| Financing cash flow | -$56.0K | -$51.0K | -$195.0K | $18.49M | $989.0K | $5.27M | $3.89M | $11.19M | -$105.0K | $3.38M | -$277.0K | $13.35M |
| Stock-based compensation | $397.0K | $352.0K | $401.0K | $711.0K | $692.0K | $955.0K | $831.0K | $825.0K | $1.76M | $1.17M | $1.24M | $1.25M |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 5.78 | 8.21 | 10.50 | 8.82 | 6.91 | 7.03 | 4.30 | 4.08 | 1.84 | 2.66 | - | 4.57 |
Source: XBRL data IN8bio Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-30, first reported Aug 7, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
INAB peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| INAB | - | - | -$19.41M | - | $9.2M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $249.05B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $207.00B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $101.48B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $57.55B |
| RVMD | $0 | - | -$1.13B | - | $41.59B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $36.71B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $16.98B |
INAB FAQ
4 questionsIs INAB profitable?
No. IN8bio Inc. reported a net loss of $19.41M for the twelve months ended Sep 30, 2026.How much cash and debt does INAB have?
IN8bio Inc. reported $14.15M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did INAB last report financial results?
The latest statements here come from IN8bio Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this INAB financial data come from?
Quantisnow builds these statements from the structured XBRL data IN8bio Inc. files with the SEC. It is provided for information only and is not investment advice.